PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy |
|
|
| Recruiting | 3 | 430 | Europe | Concomitant coaching | AIO-Studien-gGmbH, Pfizer, Crolll Gmbh | Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | 01/24 | 07/24 | | |
